Persica Pharmaceuticals is a UK-based clinical-stage biotech company developing PP‑353, a novel injectable antibiotic treatment for chronic low back pain linked to Modic changes—a spinal disc infection present in around 25% of patients. Unlike conventional therapies that focus on symptom relief, PP‑353 targets the root cause by delivering antibiotics directly to the infection site using a thermosensitive gel, enabling high local efficacy with minimal systemic exposure. Early clinical trials have shown promising results, including significant reductions in pain and disability lasting up to a year. The company is now advancing toward Phase 3 trials and exploring partnerships to bring this targeted, non-opioid therapy to market.